Gland Pharma Share Price Target 2026: Stock Analysis, Share Price Today, Bull Case and Bear Case After Q1 FY27
- June 25, 2026
- Posted by: Kunal Singla
- Category: News
Gland Pharma Rs 2,911.50 (5 Oct 2026 close). 52-week range Rs 1,573.60 to Rs 3,042. Q1 FY27 PAT Rs 317 cr, up 47%.
Quick Answer
The Gland Pharma share price target for 2026 is Rs 2,760 to Rs 3,128, which is between 5 percent below and 7 percent above the last close of Rs 2,911.50, with bull and bear cases of Rs 3,672 to Rs 4,104 and Rs 1,872 to Rs 2,160. Gland Pharma reported Q1 FY27 revenue up 20 percent to Rs 1,800 crore and profit up 47.1 percent to Rs 317 crore, with EBITDA margin at 27.2 percent and US revenue up 32 percent to Rs 981 crore. Motilal Oswal initiated coverage with a Buy and a target of Rs 3,080, the stock jumped 12 percent on 11 August to a high of Rs 2,988.40, and it is up about 51 percent in a year. No brokerage price target was available on the sources we track as of 5 October 2026, so every range below is a Univest research scenario.
The Gland Pharma share price target for 2026 is Rs 2,760 to Rs 3,128 in the Univest base case, with the stock at Rs 2,911.50 at the 5 October 2026 close. That is 4.3 percent below its 52-week high of Rs 3,042.00 and 85.0 percent above its 52-week low of Rs 1,573.60, and the stock moved up 51.4 percent over the past year. Gland Pharma makes complex injectables for global markets, with a CDMO business that is about half of revenue and a European unit, Cenexi. Debt to equity is 0.03.
Three things changed since the last update: Q1 FY27 results on 10 August showed profit up 47 percent, the stock jumped 12 percent the next day, and Cenexi is guided to revenue of EUR 200 million for FY27. This Gland Pharma stock analysis covers the Gland Pharma share price today, the Gland Pharma share price target for 2026, 2027 and 2030, the Q1 FY27 numbers, catalysts and risks, key price levels and a Gland Pharma buy or sell view.
Click Here – Get Free Investment Predictions
What Is the Gland Pharma Share Price Target for 2026?
The 2026 target for Gland Pharma shares is Rs 2,760 to Rs 3,128 in the Univest base case, which is -5.2% to +7.4% against the last close. The bull case is Rs 3,672 to Rs 4,104 and the bear case is Rs 1,872 to Rs 2,160. Motilal Oswal initiated coverage with a Buy rating and a target of Rs 3,080, according to a market report in August 2026. Analyst consensus is used as a cross-check, not as the base.
Gland Pharma Share Price Target Scenarios: Bull Case, Base Case and Bear Case
| Scenario | FY28E EPS | Target Multiple | Price Target (Rs) | Move vs Rs 2,911.50 |
|---|---|---|---|---|
| Bull Case | Rs 108 | 34x to 38x | 3,672 to 4,104 | +26.1% to +41.0% |
| Base Case | Rs 92 | 30x to 34x | 2,760 to 3,128 | -5.2% to +7.4% |
| Bear Case | Rs 72 | 26x to 30x | 1,872 to 2,160 | -35.7% to -25.8% |
FY28 EPS of Rs 92 in the base case is above trailing EPS of Rs 68.41 and assumes revenue growth near 15 percent with EBITDA margin near 27 percent. Motilal Oswal’s target sits inside the base range, and the bear case assumes US pricing falls and Cenexi stays at low margin. The PE multiple used for each case is shown in the table, and the EPS estimate is a Univest assumption, not company guidance. Those assumptions set the Gland Pharma share price target range around the current price.
Gland Pharma Company Overview and Share Price Today as of 5 October 2026
Gland Pharma share price today is Rs 2,911.50 on the NSE at the 5 October 2026 close, before the market opened on 6 October. The market capitalisation is Rs 48,068 crore, and the stock trades at 42.6 times earnings against an industry average of 37.5 times. The Univest base case Gland Pharma share price target of Rs 2,760 to Rs 3,128 is -5.2% to +7.4% from here. The table below sets out the key numbers behind the Gland Pharma share price target.
| Parameter | Value | Context |
|---|---|---|
| NSE Ticker | GLAND | BSE code 543245 |
| Sector | Injectables and CDMO | Per Univest sector classification |
| Last Close (NSE) | Rs 2,911.50 | 5 Oct 2026 close |
| 52-Week High | Rs 3,042.00 | CMP is 4.3% below |
| 52-Week Low | Rs 1,573.60 | CMP is 85.0% above |
| 1-Year Return | About +51% | Weekly close Rs 1,923.40 on 3 Oct 2025 to Rs 2,911.50 |
| Market Capitalisation | Rs 48,068 crore | Mid cap pharma company |
| Trailing P/E | About 42.6x | Industry P/E about 37.5x |
| P/B Ratio | About 4.64x | Book value Rs 627.71 per share |
| EPS (TTM) | Rs 68.41 | Trailing twelve months |
| Return on Equity | About 9.9% | Debt to equity 0.03 |
| Dividend Yield | About 0.69% | Dividend paid yearly |
| 12-Month Target (Base Case) | Rs 2,760 to Rs 3,128 | Univest base case |
| Bull Case | Rs 3,672 to Rs 4,104 | +26.1% to +41.0% |
| Bear Case | Rs 1,872 to Rs 2,160 | -35.7% to -25.8% |
Track live price, fundamentals and results for Gland Pharma on the Univest Screener.
How Did Gland Pharma Perform in Q1 FY27?
Gland Pharma reported Q1 FY27 consolidated revenue of Rs 1,800.3 crore, up 20 percent, EBITDA of Rs 493 crore, up 33 percent, and net profit of Rs 317 crore, up 47.1 percent from Rs 215 crore. EBITDA margin was 27.2 percent against 24.4 percent. Together these Q1 FY27 numbers anchor the Gland Pharma share price target.
| Metric | Q1 FY27 | Context |
|---|---|---|
| Consolidated Revenue | Rs 1,800.3 crore | Up 20% year on year |
| EBITDA | Rs 493 crore | Up 33%; margin 27.2% vs 24.4% |
| Net Profit | Rs 317 crore | Up 47.1% from Rs 215 crore |
| US Revenue | Rs 981 crore | Up 32%; 54% of revenue |
| Cenexi Revenue | EUR 48 million | EBITDA EUR 2 million |
| Gross Margin | About 65% | Stable |
Cenexi’s FY27 revenue guidance is EUR 200 million with a goal of double-digit EBITDA margin by year end. The company announced a new CDMO contract and received fresh ANDA approvals. The FY27 outlook from management is the main input for these estimates. These numbers sit behind every range in the scenario table above, so they anchor the Gland Pharma share price target.
Why Did Gland Pharma Share Price Rise 51 Percent in a Year?
Gland Pharma shares rose about 51 percent in a year because profit is growing faster than revenue and Cenexi is recovering. The stock climbed from Rs 1,573.60 in the week of 16 March 2026 to Rs 3,042 in the week of 7 September.
A jump of 25 percent in the week of 18 May on 1.26 crore shares and 14 percent in the week of 10 August on 1.18 crore shares drove the rally. The stock has traded between Rs 2,792 and Rs 3,042 since August. The Gland Pharma share price target scenarios below account for that move.
Key Catalysts for the Gland Pharma Share Price Target in 2026
4 catalysts matter most for the Gland Pharma share price target, and sector tailwinds in Injectables and CDMO are part of the case. Together they decide whether the base case is reached.
1. US Injectables Growth
US revenue rose 32 percent to Rs 981 crore on new launches. More ANDA approvals keep the pipeline full. If it plays out, the Gland Pharma share price target moves toward the top of the base range.
2. CDMO Contracts
The CDMO business is about half of revenue, and a new contract was announced. Contract work gives steadier, higher-margin income. Strength here would support the upper end of the Gland Pharma share price target.
3. Cenexi Recovery
Cenexi earned EUR 2 million of EBITDA on EUR 48 million of revenue, with a double-digit margin goal. Profit there lifts group margin. Delivery on this point keeps the Gland Pharma share price target on track.
4. Margin Expansion
EBITDA margin rose 280 basis points to 27.2 percent on scale benefits. Holding it supports EPS of Rs 92. Better news here would lift the Gland Pharma share price target toward the bull case.
What Are the Key Risks to the Gland Pharma Share Price Target?
The main risks are US price erosion, Cenexi margin, regulatory inspections and a premium valuation. Each can pull the Gland Pharma share price target lower.
US Price Erosion
Generic injectable prices can fall as rivals launch. Lower prices would cut the 27 percent margin. If it materialises, the Gland Pharma share price target would slip toward the bear case.
Cenexi Margin
Cenexi earns only about 4 percent EBITDA margin. A delay in recovery would hold group margin down. This is the main downside risk to the Gland Pharma share price target.
Regulatory Inspections
A warning letter or import alert at a plant would stop shipments. Inspection results drive the US business. A worsening here would cut the Gland Pharma share price target toward the low end of the range.
Premium Valuation
The stock trades at 42.6 times earnings and 4.6 times book. A de-rating toward 26 times FY28 EPS of Rs 72 would put the price near Rs 1,870. Watch it closely, because it can pull the Gland Pharma share price target lower quickly.
Gland Pharma Stock Analysis: Support and Resistance Levels for the Share Price Target
Gland Pharma stock analysis on weekly charts shows a range of Rs 2,792 to Rs 3,042 since mid-August, with the stock near the middle.
The first support level is Rs 2,841 to Rs 2,875, the lows of the weeks of 28 September and 5 October. Below that, Rs 2,776 to Rs 2,792 marks the August and September lows, and a weekly close under Rs 2,841 would weaken the base.
The first resistance level is Rs 2,978 to Rs 3,042, the highs of the weeks of 14 September, 28 September and 7 September. These levels come from weekly price action, are not trade recommendations, and frame the near-term Gland Pharma share price target.
Gland Pharma Share Price Target 2026, 2027 and 2030: Short, Medium and Long Term
Short-Term Gland Pharma Share Price Target (3 to 6 Months)
In the near term the stock is likely to trade between Rs 2,841 and Rs 3,042, the range of the past six weeks. A close above Rs 3,042 would open untested ground above the 52-week high, while a weekly close under Rs 2,841 would put Rs 2,776 in play. The Q2 FY27 results are the main trigger. This range anchors the near-term Gland Pharma share price target.
12-Month and 2027 Gland Pharma Share Price Target
The 12-month target price is Rs 2,760 to Rs 3,128, valued on 30 to 34 times FY28 EPS of Rs 92. The range across scenarios runs from Rs 1,872 in the bear case to Rs 4,104 in the bull case.
Long-Term Gland Pharma Share Price Target for FY29 to 2030
For FY29 to 2030 the Univest scenario range is Rs 3,500 to Rs 4,800. This assumes EPS of Rs 125 in FY29 and Rs 150 in FY30 and a multiple of 28 to 32 times. It needs CDMO growth and a double-digit Cenexi margin. This is the long-term Gland Pharma share price target in the Univest scenarios.
Bull Case and Bear Case for Gland Pharma Share Price Target
Bull Case Rs 3,672 to Rs 4,104
The bull case of Rs 3,672 to Rs 4,104 for the Gland Pharma share price target needs EPS of Rs 108 and the market to pay 34 to 38 times for it. It is +26.1% to +41.0% from the last close.
Bear Case Rs 1,872 to Rs 2,160
The bear case of Rs 1,872 to Rs 2,160 for the Gland Pharma share price target equals 26 to 30 times FY28 EPS of Rs 72 and sits well above the Rs 1,573 low. It is -35.7% to -25.8% from the last close.
Is Gland Pharma a Good Buy at Rs 2,912? Gland Pharma Buy or Sell View
Whether Gland Pharma is a buy at Rs 2,911.50 depends on horizon and risk appetite. The base case implies -5 to 7 percent from here, Motilal Oswal’s Rs 3,080 target sits inside the base range, and the open question is Cenexi. The Gland Pharma share price target range is the starting point for that decision.
Long-term holders may focus on CDMO growth, the US pipeline and the margin, and treat Rs 2,841 as the level to watch. Short-term traders may prefer to wait for a close above Rs 3,042. Check institutional holding in the September quarter filing for signs of accumulation or selling. Consult a SEBI-registered advisor before acting, since this Gland Pharma buy or sell view is educational.
How to Invest in Gland Pharma Shares
Step 1: Check the live price, valuation and the latest Gland Pharma share price target range on the Univest Screener.
Step 2: Open a demat and trading account with a SEBI-registered broker such as Univest before acting on any Gland Pharma share price target.
Step 3: Search for GLAND on the NSE or 543245 on the BSE in your trading app.
Step 4: Place a limit order near your planned entry and size the position so a fall to Rs 1,872 is bearable.
Step 5: Track US launches, Cenexi margin and Q2 FY27 results and set price alerts on the Univest App to follow any change in the Gland Pharma share price target.
Conclusion
Gland Pharma closed at Rs 2,911.50 against a Univest base case share price target of Rs 2,760 to Rs 3,128, a bull case of Rs 3,672 to Rs 4,104 and a bear case of Rs 1,872 to Rs 2,160. Q1 FY27 delivered a 47.1 percent profit rise to Rs 317 crore, with EBITDA margin at 27.2 percent and US revenue up 32 percent. The main risks are US price erosion, Cenexi margin and valuation.
The stock is 4.3 percent below its 52-week high, so the base case implies roughly -5 to 7 percent from here. The triggers to watch are US launches, the Q2 FY27 results and the Rs 2,841 and Rs 3,042 levels. Re-check the Gland Pharma share price target after each quarterly result. Investors with a long horizon and tolerance for volatility can track these triggers, while others may prefer to size positions carefully.
Download the Univest iOS App or Univest Android App to track Gland Pharma live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Gland Pharma Share Price Target 2026
What is the Gland Pharma share price target for 2026?
Ans. The Gland Pharma share price target for 2026 is Rs 2,760 to Rs 3,128 in the Univest base case, with a bull case of Rs 3,672 to Rs 4,104 and a bear case of Rs 1,872 to Rs 2,160. Motilal Oswal initiated coverage with a Buy rating and a target of Rs 3,080, according to a market report in August 2026. These are estimates and can change after the Q2 FY27 results.
What is the Gland Pharma share price target for 2027?
Ans. The Gland Pharma share price target for 2027 is Rs 2,760 to Rs 3,128 in the base case, valued on 30 to 34 times FY28 EPS of Rs 92. The scenario range runs from Rs 1,872 to Rs 4,104.
Is Gland Pharma a good buy at Rs 2,911.50?
Ans. Whether Gland Pharma is a good buy at Rs 2,911.50 depends on your horizon, risk appetite and how you read the Gland Pharma share price target. Profit is growing 47 percent and a brokerage has a Buy, but the stock is up 51 percent in a year and trades at about 43 times earnings. Consult a SEBI-registered advisor before investing.
What are the key risks to the Gland Pharma share price target?
Ans. The key risks to the Gland Pharma share price target are us price erosion, cenexi margin, regulatory inspections and premium valuation. Generic injectable prices can fall as rivals launch. Lower prices would cut the 27 percent margin.
What are the key catalysts for the Gland Pharma share price target?
Ans. The key catalysts for the Gland Pharma share price target are us injectables growth, cdmo contracts, cenexi recovery and margin expansion. US revenue rose 32 percent to Rs 981 crore on new launches. More ANDA approvals keep the pipeline full.
Where can I track Gland Pharma share price today and Gland Pharma share price target updates?
Ans. You can track the live Gland Pharma share price, results and any change to the Gland Pharma share price target on the Univest Screener and the Univest App. Download the Univest iOS App or Univest Android App for research from SEBI-registered analysts.
What are Gland Pharma’s 52-week high and low?
Ans. Gland Pharma’s 52-week high is Rs 3,042.00 and its 52-week low is Rs 1,573.60, based on weekly NSE data. At Rs 2,911.50 the stock is 4.3 percent below the high and 85.0 percent above the low. Both levels frame the Gland Pharma share price target.
How to buy Gland Pharma shares?
Ans. Open a demat account with a SEBI-registered broker such as Univest, search for GLAND on the NSE or 543245 on the BSE, and place a limit order near your entry price, using the Gland Pharma share price target range as a guide. Size the position so a fall to Rs 1,872 is bearable, and check the live price on the Univest Screener first.
